Microbiologists Display Prototype of Rapid Bacteriological Test Device
By LabMedica International staff writers Posted on 16 May 2016 |
Image: A smartphone readout from the Polarization Anisotropy Diagnostics (PAD) system reveals the pathogens responsible for an infection and factors such as antibiotic resistance (Photo courtesy of Dr. Chen-Han Huang and Dr. Ki Soo Park, Massachusetts General Hospital).
A prototype rapid diagnostic device was shown in a proof-of-concept study to identify pathogenic microorganisms with accuracy comparable to that of bacterial culture but with much shorter turnaround time.
Investigators at Massachusetts General Hospital (Boston, USA) based their device on the principle of fluorescence anisotropy, the phenomenon where the light emitted by a fluorophore has unequal intensities along different axes of polarization. Their "Polarization Anisotropy Diagnostics" (PAD) device uses changes of fluorescence anisotropy when detection probes recognize target bacterial nucleic acids.
The compact PAD device included a disposable cartridge for sample preparation and multi-well detection. To perform the test bacterial RNA was extracted from a sample in the disposable plastic cartridge. Following polymerase chain reaction amplification of the RNA, the material was loaded into a two-centimeter plastic cube containing optical components that detected target RNAs based on the response to a light signal of sequence-specific detection probes. These optical cubes were placed on an electronic base station that transmitted data to a smartphone or computer where the results were displayed.
The assay was fast (two hours) compared to two to three days for classical culture. When applied to clinical samples obtained from interventional procedures, the PAD determined the overall bacterial burden, differentiated bacterial species, and identified drug resistance and virulence status.
"This prototype still needs several improvements, including building a self-contained system housing all functions, further reducing the current assay time to less than one hour and expanding the panel of probes to even more pathogens and resistance factors," said senior author Dr. Hakho Lee, associate professor of radiology at Massachusetts General Hospital. "But we can see three immediate applications for a system that can provide such rapid and accurate results - quickly diagnosing a patient's infection, determining whether antibiotic-resistant bacteria are present in a group of patients, and detecting bacterial contamination of medical devices or patient environments."
The PAD device was described in the May 5, 2016, online edition of the journal Science Advances.
Related Links:
Massachusetts General Hospital
Investigators at Massachusetts General Hospital (Boston, USA) based their device on the principle of fluorescence anisotropy, the phenomenon where the light emitted by a fluorophore has unequal intensities along different axes of polarization. Their "Polarization Anisotropy Diagnostics" (PAD) device uses changes of fluorescence anisotropy when detection probes recognize target bacterial nucleic acids.
The compact PAD device included a disposable cartridge for sample preparation and multi-well detection. To perform the test bacterial RNA was extracted from a sample in the disposable plastic cartridge. Following polymerase chain reaction amplification of the RNA, the material was loaded into a two-centimeter plastic cube containing optical components that detected target RNAs based on the response to a light signal of sequence-specific detection probes. These optical cubes were placed on an electronic base station that transmitted data to a smartphone or computer where the results were displayed.
The assay was fast (two hours) compared to two to three days for classical culture. When applied to clinical samples obtained from interventional procedures, the PAD determined the overall bacterial burden, differentiated bacterial species, and identified drug resistance and virulence status.
"This prototype still needs several improvements, including building a self-contained system housing all functions, further reducing the current assay time to less than one hour and expanding the panel of probes to even more pathogens and resistance factors," said senior author Dr. Hakho Lee, associate professor of radiology at Massachusetts General Hospital. "But we can see three immediate applications for a system that can provide such rapid and accurate results - quickly diagnosing a patient's infection, determining whether antibiotic-resistant bacteria are present in a group of patients, and detecting bacterial contamination of medical devices or patient environments."
The PAD device was described in the May 5, 2016, online edition of the journal Science Advances.
Related Links:
Massachusetts General Hospital
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia